

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
1	18/WS/0137	247036	VISION Study of 177Lu-PSMA-617 in the treatment of PSMA-Positive mCRPC	25/07/2018	01/10/2018	10/09/2018	17/10/2018	18/10/2018	26/10/2018	28/12/2018	NHS Provider
2	18/LO/0723	244615	AFTER study	11/09/2018	03/10/2018	02/07/2018	23/11/2018	11/12/2018	11/12/2018	13/12/2018	NHS Provider
3	18/LO/1223	244752	RPC01-3203:study of Ozanimod as Maintenance therapy for Crohns Disease	11/04/2018	12/10/2018	18/09/2018	22/10/2018	06/11/2018	13/03/2019		Sponsor
4	17/NE/0358	220871	RPC01-3204: Open Label Extension study of Ozanimod for Crohn's Disease	11/04/2018	12/10/2018	18/09/2018	22/10/2018	06/11/2018	13/03/2019		Sponsor
5	17/LO/1590	229278	My-CRA, Liquid 13 Cis Retinoic Acid	03/07/2018	15/10/2018	04/01/2018	17/10/2018	18/10/2018	19/10/2018	30/11/2018	Benchmark Met
6	18/LO/1311	248599	Cytosponge for post-chemoradiation surveillance of oesophageal cancer	15/06/2018	15/10/2018	23/01/2018	15/10/2018	30/11/2018	18/12/2018	06/02/2019	Sponsor
7	18/EM/0228	248988	UK Mini Mitral	07/09/2018	19/10/2018	19/07/2016	05/11/2018	16/11/2018	06/12/2018	11/01/2019	Sponsor
8	18/SC/0472	234266	A Phase III Randomized Double-blind Trial of Pembrolizumab (MK-3475) (SCH-900475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Gastric or Gastroesophageal...	24/08/2018	24/10/2018	27/10/2017	23/10/2018	26/11/2018	10/01/2019	03/04/2019	Neither
9	17/NI/0096	225743	ILUMIEN IV: OPTIMAL PCI	02/08/2018	26/10/2018	25/10/2018	03/12/2018	07/12/2018	11/12/2018	10/01/2019	Sponsor
10	18/LO/0165	224726	GR40398 EFFICACY AND SAFETY OF RO6867461 IN DMO PATIENTS (RHINE) v1	07/06/2018	26/10/2018	03/10/2018	24/10/2018	29/10/2018	09/11/2018	24/04/2019	NHS Provider
11	18/SC/0358	230456	Anti-viral effect of PC786 on RSV infection in HSCT recipients	19/06/2018	31/10/2018	21/08/2018	02/11/2018	02/11/2018	21/11/2018	16/01/2019	Sponsor
12	17/SC/0536	216069	ProMPT-2	07/09/2018	06/11/2018	24/10/2018	06/11/2018	27/11/2018	11/01/2019	05/02/2019	Sponsor
13	18/LO/1238	245332	HOPE-1	11/10/2018	09/11/2018	14/07/2017	15/11/2018	16/11/2018	26/11/2018	15/01/2019	Benchmark Met
14	18/EE/0373	249396	POLEM	14/09/2018	15/11/2018	09/05/2018	15/11/2018	23/01/2019	28/02/2019	09/07/2019	Both
15	18/LO/1450	248611	Interleukin-2 Therapy of Autoimmunity in Diabetes	07/08/2018	16/11/2018	13/08/2018	11/12/2018	12/12/2018	28/01/2019		Sponsor
16	18/NW/0812	254035	Open Label Extension study of WVE-210201 in patients with DMD	04/10/2018	14/01/2019	25/10/2018	01/02/2019	19/02/2019	07/03/2019	08/05/2019	Neither
17	18/SC/0243	240684	Early valve surgery for severe asymptomatic aortic stenosis (EVoLVeD)	11/09/2018	27/11/2018	17/06/2017	25/02/2019	25/02/2019	03/04/2019	16/04/2019	Sponsor
18	18/SC/0016	191852	COPELIA	16/10/2018	29/11/2018	04/12/2017	29/11/2018	04/01/2019	18/01/2019	31/01/2019	Benchmark Met
19	17/LO/1622	219932	Breast Cancer Her 2	15/05/2018	17/01/2019	19/01/2019	22/02/2019	25/02/2019	08/03/2019	16/05/2019	Neither
20	19/EM/0003	251874	Marigold Study 4407/0001 Marinus	18/10/2018	21/01/2019	07/12/2018	29/01/2019	29/01/2019	06/02/2019	14/05/2019	Neither
21	18/NE/0312	245315	CAIN457M2301 (SUNSHINE): Secukinumab in hidradenitis suppurativa	02/11/2018	21/01/2019	16/01/2019	31/01/2019	04/02/2019	22/02/2019		Neither
22	18/EE/0378	248600	ORION-4	25/07/2018	04/02/2019	17/10/2018	22/02/2019	28/02/2019	01/05/2019	15/05/2019	Sponsor
23	18/NE/0264	250542	Focus: A study to test a new treatment for dry AMD	19/02/2018	11/02/2019	23/04/2018	10/01/2019	15/02/2019	18/02/2019	29/05/2019	Neither

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
24	18/SS/0010	238051	Phase 3 - XL184 in Combination with Atezolizumab vs Sorafenib in HCC	11/12/2018	12/08/2019	15/02/2019	18/07/2019	12/08/2019	20/08/2019		70 days Not yet reached
25	18/LO/0745	231612	Phase 3 Study of Edasalonexent in Duchenne Muscular Dystrophy	21/12/2018	27/02/2019	20/02/2019	21/03/2019	22/03/2019	22/03/2019	30/04/2019	Benchmark Met
26	18/SC/0242	238151	LTE Efficacy / Safety Study Of PF-04965842, w/wo T'cal Meds, in Subjs 12+ years with Mod to Sev AD	27/11/2018	19/03/2019	16/11/2018	15/02/2019	22/03/2019	19/06/2019	20/06/2019	Neither
27	19/EM/0047	257111	TACE-3	14/01/2019	05/09/2019	21/03/2019					70 days Not yet reached
28	19/NI/0032	242580	Conbercept in Neovascular Age-related Macular Degeneration	20/11/2018	21/03/2019	10/01/2019	27/03/2019	28/03/2019	18/04/2019	17/05/2019	Benchmark Met
29	18/WA/0420	246637	TRACKER	05/02/2019	25/03/2019	27/09/2018	26/03/2019	27/03/2019	28/03/2019		Sponsor
30	18/EE/0099	239606	CL3-95005-006 SOLSTICE	08/02/2019	01/05/2019	01/06/2018	01/05/2019	03/05/2019	30/05/2019	13/06/2019	Benchmark Met
31	18/LO/1187	240011	Idera 2125-MEL-301	20/07/2017	30/05/2019	24/04/2019	19/06/2019	19/06/2019	19/06/2019	20/06/2019	Benchmark Met
32	17/YH/0187	218853	FORCE - Forearm fracture Recovery in Children Evaluation	11/10/2018	14/01/2019	16/11/2018	14/01/2019	04/02/2019	13/02/2019	14/02/2019	Benchmark Met
33	19/SC/0113	241916	Service-review and Feasibility Trial in Paediatric Weight Management	11/01/2019	21/01/2019	08/11/2018	04/02/2019	04/02/2019	03/07/2019	10/07/2019	Sponsor
34	18/SW/0045	239151	1011712	25/09/2018	31/01/2019	03/01/2019	06/02/2019	08/02/2019	27/05/2019		Sponsor
35	19/LO/1024	263894	NeoCLEAR	29/11/2018	06/02/2019	12/06/2018	06/02/2019	09/05/2019	09/05/2019	23/05/2019	Sponsor
36	17/LO/1875	219487	Inotuzumab Ozogamicin for treatment of pediatric BCP-ALL	23/03/2017	13/02/2019	12/02/2018	13/02/2019	10/05/2019	13/05/2019		Neither
37	19/NW/0106	257112	Erdaftinib compared with Vinflunine or Docetaxel or Pembrolizumab	06/03/2018	04/04/2019	21/03/2018	27/03/2019	09/04/2019	10/04/2019	14/06/2019	Neither
38	19/NW/0174	261666	IL-1 Signal Inhibition in Alcoholic Hepatitis (Isaiah)	21/11/2018	08/04/2019	11/07/2018	03/05/2019	09/05/2019	16/05/2019		Neither
39	19/EM/0063	253607	BLING III study	25/06/2018	09/04/2019	24/08/2018	16/04/2019	18/06/2019	24/06/2019	25/06/2019	Sponsor
40	19/EE/0105	259619	GR40306 (TENAYA): A study of faricimab in nAMD	05/11/2018	10/04/2019	04/04/2019	08/04/2019	15/04/2019	30/04/2019	05/06/2019	Benchmark Met
41	18/SC/0342	247085	LYMRIT-37-07 - Study of safety and efficacy of Betalutin and rituximab in patients with FL	14/01/2019	17/04/2019	01/04/2019	25/04/2019	21/05/2019	16/08/2019		Neither
42	19/SW/0039	253195	Spironolactone for Adult Female Acne	21/01/2019	26/04/2019	04/02/2019	03/06/2019	11/06/2019	24/06/2019	23/07/2019	Sponsor
43	19/YH/0067	254066	ATHENA - a first line ovarian cancer maintenance trial.	31/07/2018	13/05/2019	11/09/2018	19/06/2019	24/06/2019	27/06/2019		Neither
44	19/LO/0952	262142	PRISM Trial	17/07/2018	24/05/2019	11/10/2017	24/05/2019	17/06/2019	05/07/2019		Neither
45	19/SC/0253	264426	Mistletoe And Breast Cancer (MAB)	11/06/2018	05/06/2019	02/04/2019	05/06/2019	20/06/2019	30/07/2019	13/09/2019	Neither
46	18/SS/0085	243640	Pembrolizumab ± SBRT in Medically Inoperable Stage I/IIA NSCLC	05/06/2019	05/06/2019	26/07/2019	06/08/2019	16/08/2019	23/08/2019		Neither

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
47	18/NE/0282	248188	Alpha-2 agonists for sedation (A2B Trial)	31/05/2019	02/08/2019	14/12/2018	09/08/2019	20/08/2019			70 days Not yet reached
48	19/SC/0086	249778	Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART)	03/07/2018	12/06/2019	08/01/2018	12/07/2019	19/07/2019	24/07/2019		Neither
49	19/YH/0013	255993	Cabozantinib in Radioiodine-Refractory Differentiated Thyroid Cancer	11/03/2019	19/08/2019	09/05/2019	31/07/2019	19/08/2019	30/08/2019		70 days Not yet reached
50	19/YH/0079	259791	Long-Term safety and efficacy of baricitinib - 14V-MC-JAHV	22/01/2019	14/06/2019	10/06/2019	04/06/2019	14/06/2019	24/06/2019	05/07/2019	Benchmark Met
51	19/EM/0020	252705	AMADEUS	11/03/2019	26/06/2019	14/05/2019	26/06/2019	30/08/2019	02/09/2019	18/09/2019	Both
52	19/NW/0442	262204	PROTECTOR	07/08/2018	25/03/2019	19/04/2018	13/05/2019	13/05/2019	24/06/2019	07/08/2019	Both
53	19/YH/0158	262107	Image guided radiotherapy and adaptive brachytherapy for cervix cancer	11/01/2019	05/04/2019	09/10/2017	05/04/2019	05/08/2019			Sponsor
54	19/LO/1057	261202	The Sunflower Study	02/10/2018	09/04/2019	12/12/2018	09/04/2019	10/04/2019	10/04/2019	15/04/2019	Benchmark Met
55	18/NW/0694	248847	PROTHOR	13/03/2019	10/04/2019	17/10/2018	10/04/2019	23/04/2019	24/04/2019	20/05/2019	Benchmark Met
56	19/YH/0247	266732	TAME Cardiac Arrest Trial	13/09/2018	11/04/2019	13/06/2018	15/05/2019	17/05/2019	20/05/2019	20/05/2019	Benchmark Met
57	18/NW/0699	241427	Conventional versus minimally invasive extra-corporeal circulation	26/02/2019	29/04/2019	29/11/2017	22/04/2019	17/05/2019	28/05/2019	02/06/2019	Benchmark Met
58	17/LO/1476	224732	TIME: Take home naloxone Intervention Multi centre Emergency setting feasibility trial	17/01/2019	16/05/2019	08/01/2019	16/05/2019	04/06/2019	13/06/2019		Neither
59	19/NW/0443	264683	OpTIMUM	08/04/2019	28/05/2019	28/03/2019	28/05/2019	03/06/2019	03/06/2019	26/06/2019	Benchmark Met
60	19/LO/0928	262406	Surgery or Cast for Injuries of the EpicoNdyle in Children's Elbows	05/06/2019	05/06/2019	25/03/2019	25/07/2019	30/07/2019	14/08/2019	17/09/2019	Both
61	19/NW/0482	269475	The FENETRE Study	06/06/2019	07/06/2019	25/03/2019	21/06/2019	21/06/2019			Sponsor
62	19/EM/0151	259687	TOXYC: Targeted OXYgen therapy in Critical illness	16/05/2019	25/06/2019	13/11/2017					
63	19/YH/0099	257815	Biliary Tract Cancer - Durva (TOPAZ-1)	19/03/2019	24/06/2019	28/05/2019					NHS Provider
64	18/SC/0427	220853	MERIT	25/07/2018	11/07/2019	07/11/2017	25/07/2019	30/07/2019			Both
65	18/SC/0281	245538	JUVE-X/ Long term safety and efficacy of baricitinib	10/04/2019	12/07/2019	24/06/2019	28/08/2019	29/08/2019			Neither
66	17/SC/0661	227234	Phase III Trial of AMT-061 in adults with haemophilia B	14/05/2019	15/07/2019	06/09/2018	09/07/2019	18/07/2019	30/07/2019		Sponsor
67	16/WA/0156	204506	GLOW	30/08/2018	16/07/2019	20/05/2019					NHS Provider
68	18/LO/1193	242628	FIRST-line support for Assistance in Breathing in Children (FIRST-ABC)	03/06/2019	19/07/2019	26/07/2019	05/09/2019	09/09/2019			Sponsor
69	17/SS/0052	196827	Red cell transfusion in Paediatric Allogeneic HSCT (RePAST)	07/05/2019	24/07/2019	24/06/2019	30/08/2019	03/09/2019	03/09/2019	18/09/2019	Benchmark Met
70	18/WM/0324	246654	CANOPY-1	23/03/2019	26/07/2019	23/04/2019	07/08/2019	14/08/2019	19/08/2019		70 days Not yet reached

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
71	18/SC/0471	242624	Phase 3 Study of Pembrolizumab plus Docetaxel in mCRPC	08/02/2019	26/07/2019	14/08/2019	05/08/2019	06/08/2019	28/08/2019		70 days Not yet reached
72	18/WS/0172	251636	Open label study of BI 754132 in patients with Geographic Atrophy.	23/05/2019	31/07/2019	08/07/2019	02/08/2019	02/08/2019	20/08/2019		70 days Not yet reached
73	18/SC/0222	223737	Extension of Study 20130173 in Children and Young Adults with OI	22/08/2018	05/08/2019	13/03/2019	16/08/2019	16/08/2019	20/08/2019		70 days Not yet reached
74	18/LO/0555	237992	A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors	19/10/2018	05/08/2019	06/06/2019					70 days Not yet reached
75	17/EE/0213	201374	EluNIR HBR study	25/03/2019	05/08/2019	19/07/2019	04/08/2019	19/08/2019	25/08/2019	20/09/2019	Benchmark Met
76	18/YH/0358	242342	TAPER	03/07/2019	21/08/2019	23/05/2019	22/08/2019	27/08/2019			70 days Not yet reached
77	18/YH/0236	230191	JUVE BRIGHT	18/06/2019	28/08/2019	06/08/2019	29/08/2019	02/09/2019	18/09/2019		70 days Not yet reached
78	17/WA/0192	227541	TRANSITION	13/06/2019	28/08/2019	26/07/2019	04/09/2019	12/09/2019			70 days Not yet reached
79	17/SW/0250	222991	Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC	08/02/2019	30/08/2019	28/08/2019	02/09/2019	12/09/2019	12/09/2019		70 days Not yet reached
80	18/WA/0337	248818	Derby - Geographic Atrophy secondary to AMD	06/08/2018	30/08/2019	07/12/2018	02/09/2019	02/09/2019			70 days Not yet reached
81	19/YH/0050	249236	4451-STEP TEENS-semaglutide effect in adolescents with obesity	24/07/2019	03/09/2019	25/09/2019					70 days Not yet reached
82	19/NW/0158	259931	High Energy High Protein Peptide Feed Study	01/08/2019	06/09/2019	13/01/2017	12/09/2019	13/09/2019			70 days Not yet reached
83	18/LO/2111	254025	A phase 2a Study in Adult Volunteers with Sickle Cell Anaemia - 001	20/06/2019	09/09/2019	19/10/2017	04/09/2019	10/09/2019	12/09/2019		70 days Not yet reached
84	16/SC/0106	186573	JAHU; Oral baricitinib in patients 1-18 years with systemic JIA	25/06/2019	11/09/2019	19/08/2019					70 days Not yet reached
85	19/EE/0185	260536	Pembrolizumab+Olaparib vs Abiraterone Acetate or Enzalutamide in mCRPC	31/05/2019	12/09/2019	02/09/2019					70 days Not yet reached
86	19/WM/0121	246398	HALT - Stereotactic Body Radiotherapy for the treatment of OPD	02/09/2019	19/09/2019	10/07/2017					70 days Not yet reached
87	19/NI/0110	260538	Kepler	18/06/2019	20/09/2019	27/09/2019					70 days Not yet reached
88	16/SC/0651	213404	Cerebral Palsy-0075/0140-Teva	19/02/2019	23/09/2019	16/07/2019					70 days Not yet reached
89	17/LO/0980	219505	A Phase IIa study of the efficacy and safety of oral LAT8881 in neuropathic pain (LAT-NP-001)	30/11/2018	26/09/2019	05/09/2019	26/09/2019				70 days Not yet reached

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
90	17/LO/1334	217338	The Bronchiolitis Endotracheal Surfactant Study (BESS)	21/06/2019	30/09/2019	15/10/2018	30/09/2019				70 days Not yet reached